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ABSTRACT
Several HIV-1 subtype C-specific gag- and/or nef-based vaccines are currently intended for clinical trial in
southern Africa. Here we provide sequences of 64 gag and 45 nef genes sampled in Malawi, Zambia, Zimbabwe,
and South Africa and assess the degree of southern African HIV-1 diversity that will confront these vaccines.
Whereas reasonable phylogenetic evidence exists for geographical clustering of subtype C gag and nef sequences
from various other parts of the world, there is little evidence of similar population founder effects in the south-
ern African epidemic. The entire breadth of subtype C diversity is represented in the southern African genes
suggesting there may be no advantage in producing region- or country-specific subtype C vaccines. We do not,
however, find much evidence of intersubtype recombination in the Southern African genes, implying that the
likelihood of vaccine failure due to the emergence of intersubtype recombinants is probably low.
SOUTHERN AFRICAN COUNTRIES are experiencing the greatestburden of the AIDS epidemic as a result of the devastating
spread of human immunodeficiency virus type 1 (HIV-1) sub-
type C.1,2 Estimated southern African adult HIV prevalence
rates of over 30% in some regions highlight the need for an ef-
fective vaccine (http://www.who.int/emc-hiv/fact_sheets/).
One of the most important challenges in vaccine design is
dealing with the high degrees of HIV-1 genetic diversity that
are a characteristic of the AIDS epidemic. Fueled by high vi-
ral mutation, recombination, and replication rates and driven by
strong host immune pressures,3,4 the diversity of global HIV
populations is continuing to increase at an astonishing rate.
There is, however, considerable variability in the rate at which
different regions of the HIV genome are diversifying. Differ-
ences in the degree of nucleotide sequence conservation across
the HIV genome reflect in part the balance that exists between
selection pressures exerted by host immune systems5 and the
functional constraints of viral proteins.6
Gag and the central region of Nef are reasonably conserved
HIV proteins with high epitope densities that are among the
most common targets of host cellular immune responses.7–9
Conflicting clinical data exist on the association between T cell
responses and plasma viremia. While some studies showed no
correlation between plasma viral load and CD8 T cell re-
sponses specific against HIV-1 p24-Gag and Nef,8,10 other stud-
ies showed an inverse correlation between HIV-1 C Gag T cell
responses and plasma viral load indicating that Gag-specific cy-
totoxic T lymphocyte (CTL) responses are possibly important
in controlling viremia.9,11 Gag and nef are therefore attractive
potential vaccine components and, accordingly, there are cur-
rently several gag- and/or nef-based vaccines intended for clin-
ical trial in southern Africa (http://www.iavireport.org/trialsdb
IAVI database of AIDS vaccines in human trials).
While there is presently a large amount of data available for
South African and Botswanan subtype C gag and nef sequences,
the same is not true for other southern African countries. There-
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fore, to better assess the degree of HIV genetic diversity con-
fronting proposed southern African subtype C-specific gag-
and/or nef-based vaccines, 64 gag and 45 nef sequences were
determined from 71 HIV-1-infected individuals recruited as part
of the HIVNET028 study9,11 from five clinical sites in south-
ern Africa: Johannesburg (n  10; gag  8; nef  6) and Dur-
ban (n  22; gag  22; nef  14) in South Africa; Lusaka in
Zambia (n  20; gag  18; nef  13); Harare in Zimbabwe
(n  9; gag  6; nef  5); and Blantyre in Malawi (n  10;
gag  10; nef  7).
Viral RNA was extracted from plasma using the QIAamp
Viral RNA Kit (QIAGEN, Chatsworth, CA) or the NASBA
RNA extractor kit (Life Sciences, Inc.). The gag and nef genes
were reverse transcribed using the ThermoScript RT-PCR Sys-
tem (Invitrogen Corp., San Diego, CA), and an oligo(dT)20
primer, and the primer Gag D reverse (5AATTCCTCCTATC-
ATTTTTGG3, at position 2382–2402 of the HXB2 genome)
and the primer nefOR (5AGGCAAGCTTTATTGAGG3, at
position 9608–9625 in HXB2), respectively. A 1673-bp full-
length gag gene product was amplified from cDNA by nested
polymerase chain reaction (PCR) using the outer primers Gag
D forward (5TCTCTAGCAGTGGCGCCCG3, at position
626–644) and Gag D reverse. Three fragments of 600 bp,
overlapping by 77 and 99 nucleotides, respectively, were gener-
ated using inner primers: Gag A forward (5CTCTCGACGC-
AGGACTCGGCTT3, 683–704) and Gag A reverse (5AC-
ATGGGTATCACTTCTGGGCT3, 1282-1303), Gag B for-
ward (5CCATATCACCTAGAACTTTGAAT3, 1226–1248)
and Gag B reverse (5CTCCCTGACATGCTGTCATCAT3,
1825–1846), and Gag C forward (5CCTTGTTGGTCCAA-
AATGCGA 3, 1748–1768) and Gag C reverse (5TCTTC-
TAATACTGTATCATCTGC3, 2334–2356). A 750-bp full-
length nef gene product was amplified from cDNA by nested
PCR using the outer primers nefOF (5GTGGAATTCCTG-
GGACG3, 8568–8584) and nefOR and inner primers nefIF 
(5 CCTAGAAGAATAAGACAGGGC3, 8754–8774) and ne-
fIR (5 CTTATATGCAGCATCTGAGG3, 9498–9517).
PCR products were purified (QIAquick PCR Purification
kit,QIAGEN, Chatsworth, CA) and sequenced with the forward
and reverse Gag A, B, and C or Nef IF and IR primers using
the BigDye Terminator Cycle sequencing kit version 3.1 (Ap-
plied Biosystems Inc., Foster City, CA) and an automated ABI
PRISM 3100 genetic analyzer (Applied Biosystems Inc.).
Full length gag and nef sequences were respectively aligned
using POA (gap open penalty  12, gap extension penalty 
4)12 with all nearly full length gag (n  1236) and nef (n 
1923) sequences available in the Los Alamos National Labo-
ratory HIV-1 sequence database (http://hiv-web.lanl.gov/con-
tent/hiv-db) on 4 August 2005 (for gag) and 10 February 2006
(for nef). Except for subtype and circulating recombinant form
(CRF) references and one HIV-1 N sequence, all sequences that
did not cluster among the subtype C sequences in a neighbor-
joining tree (transition:transversion ratio  2.0, constructed
with PHYLIP v3.5c)13 were discarded to obtain gag and nef
datasets containing 558 and 677 sequences, respectively. These
datasets were realigned using POA and potential inter- and in-
trasubtype recombinants among the HIVNET028 sequences
were identified using six recombination detection methods im-
plemented in RDP3 (default settings for all methods and a Bon-
ferroni corrected p-value cutoff  0.05).14
None of the HIVNET028 gag or nef sequences were identi-
fied as being intersubtype recombinants. However, eight
HIVNET028 gag and three HIVNET028 nef sequences were
identified by two or more recombination detection methods as
being intrasubtype C recombinants. Recombination can seri-
ously impact the validity of phylogenetic inferences15,16 and we
therefore removed the pieces of these HIVNET028 sequences
that appeared to have a recombinant origin. Sequences between
the approximate recombination breakpoints identified for the
11 detected events were replaced in the alignment with gap
characters. In no case was more than 39% of a sequence re-
placed by gap characters. To further minimize the impact of re-
combination on subsequent phylogenetic reconstructions, 163
potentially recombinant gag sequences and 245 potentially re-
combinant nef sequences, identified by any one of the six re-
combination detection methods with the same Bonferroni p-
value correction used to identify HIVNET028 recombinants,
were completely removed from the gag and nef alignments. An
additional 14 gag and 8 nef sequences identified elsewhere as
being intersubtype recombinants but that were not identified as
such during the recombination screen were also removed from
the gag and nef datasets.
None of the HIVNET028 sequences was more closely re-
lated to previously identified intersubtype recombinants with
subtype C-like gag or nef sequences than to other apparently
“pure” subtype C sequences. Also, during the initial recombi-
nation screen we noted that only three Zambian, one
Botswanan, and two South African gag sequences and one
Botswanan and three South African nef sequences were prob-
able intersubtype recombinants. All of these sequences are pre-
viously identified recombinants, but none is a recognized CRF.
Our analyses indicated, however, that A2C.ZM.x.ZAM716 and
A2C.ZM.89.ZAM174 share nearly identical breakpoints in gag
and may be examples of a recombinant form currently circu-
lating in Zambia. That only 7.8% of the 64 potentially recom-
binant southern African gag sequences and 3.1% of the 127
potentially recombinant Southern African nef sequences are in-
tersubtype recombinants indicates that there is evidence of only
limited gene flow from other subtypes or CRFs into the region’s
overwhelmingly subtype C HIV population. This implies, first,
that most all non-C subtypes and all recognized CRFs are ei-
ther very rare or absent from southern Africa, and second, that
there may be a degree of epidemiological isolation between sub-
type C and the other HIV-1 subtypes that have been identified
in the region (such as A, B, and D).
The 373 gag and 421 nef sequences retained following elim-
ination of potential recombinants were realigned with POA and
used to construct neighbor-joining trees (Fig. 1; with transi-
tion:transversion ratios estimated from the alignments, pairwise
deletion of indels, and 1000 bootstrap and branch length test
replicates) with MEGA 3.0.17
Both the gag and nef phylogenetic analyses provide clear ev-
idence of geographical clustering of subtype C isolates in var-
ious parts of the world. South American isolates (mostly from
Brazil) form single well-supported monophyletic groups
(70% bootstrap and  95% branch length test support) in
both the gag and nef trees. Also in both trees, the Indian iso-
lates mostly fall into one of two groups. Whereas both groups
are well supported (70% bootstrap and 99% branch length
test support) in the nef tree, only one is well supported in the
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FIG. 1. Neighbor-joining trees indicating the phylogenetic relationships between 382 gag (A) and 430 nef (B) HIV-1 subtype C se-
quences. The trees were constructed using Kimura, 1980 distance matrices with transition:transversion ratios estimated from the data
and pairwise deletion of indels (Mega 3.0 Kumar et al., 2004). Colored symbols at the ends of branches represent sequences sampled
from different regions of the world. Open symbols with a red border represent the 64 gag and 44 nef sequences sampled from South-
ern Africa during the present study. Both trees were rooted using the HIV-1 subtype B isolate, HXB2, as an out-group and the sig-
nificance of their interior branches tested using 1000 bootstrap and interior branch length test replicates. Solid and open black circles
indicate branches with greater that 70% and 50% bootstrap support, respectively. All branches with less than 50% bootstrap support
and less than 70% interior branch length test support have been collapsed. The arrow indicates a divergent subtype C-like gag se-
quence from Zambia. While the trees were constructed using an additional HIV-1 group N sequence and nine HIV-1 M subtype and
subsubtype reference sequences, only the HIV-1 M subtype B reference sequence is shown.
gag tree. The South East Asian subtype C sequences (mostly
from China) are clearly most closely related to isolates in one
or the other Indian groups, indicating linkage between these
epidemics. In contrast, the subtype C epidemic in South Korea
(nef tree in Fig. 1) has not been obviously founded by viruses
from either India or South East Asia. In fact the Korean viruses
most closely resemble divergent subtype C isolates from South-
ern Africa and it is possible that this is their origin.
Within Africa there is also some evidence of geographical
clustering of subtype C lineages. For example, the Ethiopian
gag and nef sequences both cluster within two weakly supported
(70% branch length test support) groups. While a close rela-
tionship between Brazilian subtype C viruses and those in one
of the Ethopian groups is implied in both the gag and nef trees,
there is also reasonable support (50% bootstrap support) in
both trees for an Ethiopian origin of Middle Eastern subtype C
viruses.
While there are small, well-supported exclusively South
African or Botswanan groups in both trees, these may be the
result of sampling bias since the overwhelming majority of
southern African sequences have been obtained from these two
countries. That sampling bias is responsible for at least some
of the apparent clustering of South African sequences is sup-
ported by the observation that only 3 of the 30 South African
HIVNET028 gag sequences and 2 of the 20 South African
HIVNET028 nef sequences exclusively group with other South
African sequences with greater than 50% bootstrap support.
Conversely, of the South African HIVNET028 sequences five
gag sequences and one nef sequence are probably (50% boot-
strap support) most closely related to non-South African se-
quences. Lack of clear geographical clustering of isolates ob-
tained from different southern Africa countries is possibly
evidence of the largely unrestricted movement of subtype C
genotypes across the entire subcontinent.
The most striking feature of the gag and nef sequence phy-
logenies is that the southern African viruses represent the en-
tire breadth of subtype C diversity. The high diversity of the
southern African sequences in general, and those sampled in
the HIVNET028 study in particular, is evidenced by the fact
that in addition to all of them obviously being subtype C se-
quences, only 11 of 64 gag sequences and 11 of 45 nef se-
quences are clearly (50% bootstrap support) most closely re-
lated to other individual subtype C sequences.
One of the HIVNET028 gag sequences from Zambia
(541–178 indicated by an arrow in Fig. 1A) is actually the most
divergent subtype C gag sequence yet identified. Sequence
541–178 is also potentially an intrasubtype C recombinant. Five
of the six methods used to detect recombination indicated that
541–178 had most likely inherited the sequence between nu-
cleotide positions 959 and 1221 from a Botswanan subtype C
virus resembling C.BW.00BW147127 (p-values  2.97 
103, 7.26  105, 1.14  103, 2.13  102, 1.66  104
for the RDP, RECSCAN, MAXCHI, CHIMAERA, and SIS-
CAN methods, respectively). Although the remainder of the
541–178 sequence is clearly subtype C-like (Fig. 1A), it repre-
sents a lineage that apparently split from the main subtype C
lineage early after the emergence of the ancestral subtype C
progenitor.
The high degrees of southern African subtype C nef and gag
gene diversity will increase the difficulty of constructing
broadly protective subtype C-specific vaccines based on these
genes. The absence of lower diversity, country-specific, south-
ern African subtype C lineages may also seriously hamper the
effective use of vaccines specifically targeting smaller subsets
of the HIV variants present in the region. On the other hand,
there is not much evidence of intersubtype gag and nef sequence
exchange among the region’s isolates. This should improve the
prospects of the predominantly nef- and gag-based vaccines set
to be tested in southern Africa in that it is unlikely that these
will fail due to the emergence of escape recombinants ex-
pressing vaccine-targeted epitopes derived from non-subtype C
viruses.
Sequences have been deposited in GenBank under the ac-
cession numbers DQ792982–DQ793089.
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